Enlivex Therapeutics announced that the Spanish Agency of Medicines and Medical Devices, AEMPS, has authorized the expansion of the Company’s Phase I/II of Allocetra in patients with advanced solid malignancies. The clearance of the Phase I/II by the AEMPS follows recent announcements by the Company that the study received IND clearance from the U.S. Food And Drug Administration for recruitment of patients in the U.S., the independent Data Safety Monitoring Board has completed its prespecified data review for the first cohort of patients in the Phase I/II trial and the Israeli Ministry of Health had reviewed the data and provided regulatory clearance to continue the study and open the subsequent high dose monotherapy and combination cohorts. The Phase I/II multi-center clinical trial has been designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors. The Phase I/II trial was initiated following encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra was combined with a PD1 checkpoint inhibitor in a murine model of ovarian cancer, and additional models that demonstrated statistically significant survival benefit when Allocetra was combined with a PD1 or CTLA-4 checkpoint inhibitors in a murine model of peritoneal mesothelioma. Einat Galamidi, MD., Vice President, Medical of Enlivex, stated "We are pleased with the AEMPS’ regulatory clearance to expand our clinical trial into Spain. We believe that AllocetraTM has the potential to provide a paradigm shift in treatment of advanced solid tumors, and we look forward to data readouts, including safety and potential indication of effect in patients, currently expected during 2023 and 2024."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ENLV:
- Enlivex Therapeutics issued Israeli patent for Allocetra
- Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
- Enlivex announces recommendation, IMOH clearance for Phase I/II trial
- Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
- Enlivex receives authorizations from French, Belgian to expand Sepsis trial